Psychedelic experience intensity during ketamine treatment and antidepressant outcomes.
David S Mathai, Sean P Goldy, Thomas D Hull, Kristin Arden, Jack Swain, Leonardo Vando, Matteo Malgaroli
Psychopharmacology November 18, 2026 DOI: 10.1007/s00213-026-07219-0 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Retrospective longitudinal cohort study Preregistered Peer reviewed |
|---|---|
| Sample size | 3,637 |
| Population | Adults with moderate-to-severe depression |
| Intervention | Sublingual ketamine |
| Duration | Up to 4 doses over 4 weeks |
| Measures | Patient Health Questionnaire-9 (PHQ-9), Mindbloom Psychedelic Intensity (MPI) scale |
| Topics | Depression Ketamine Esketamine |
| Keywords | Antidepressant response Precision psychiatry Psychedelic experience Subjective effects |
| Key findings | Higher subjective psychedelic intensity scores at two weeks were associated with greater reductions in depression severity at four weeks, increased likelihood of clinically significant change, and greater likelihood of membership in an improvement trajectory, independent of dose and other covariates. The authors conclude that subjective drug effects are a clinically meaningful correlate of treatment response. |
Abstract
Ketamine is an effective antidepressant, but the role of acute subjective effects in treatment response remains unclear. Prior studies rely largely on dissociation measures focused on adverse events, which may not capture broader effects across multiple phenomenological domains. To evaluate whether subjective psychedelic intensity during ketamine treatment, considered beyond an adverse-event framework, is associated with antidepressant outcomes. In this retrospective longitudinal cohort study, 3,637 adults with moderate-to-severe depression received up to 4 doses of sublingual ketamine over 4 weeks within a telehealth-supported treatment program. Subjective effects were assessed using the Mindbloom Psychedelic Intensity (MPI) scale, a novel 5-item measure capturing emotional, cognitive, physical, visual, and auditory effects. Primary outcomes included end-of-treatment change in Patient Health Questionnaire-9 (PHQ-9) scores, clinically significant change, and treatment response trajectories. Pre-registered analyses evaluated whether MPI scores at the midpoint of treatment were associated with antidepressant outcomes. Higher subjective intensity scores at 2 weeks were associated with greater reductions in depression severity at 4 weeks, increased likelihood of clinically significant change, and greater likelihood of membership in an improvement trajectory, independent of dose and other covariates. Subjective intensity of the ketamine experience was robustly associated with antidepressant outcomes. These findings suggest that subjective drug effects represent a clinically meaningful correlate of treatment response and highlight the importance of assessments designed to capture first-person experiences with ketamine, with implications for future mechanistic research and clinical care.